The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Targeting the PI3-kinase pathway in triple-negative breast cancer
Open accessAbstract
Triple negative breast cancer (TNBC) is characterised by poor outcomes and a historical lack of targeted therapies. Dysregulation of signalling through the PI3 kinase and AKT signalling pathway is one of the most frequent oncogenic aberrations of triple negative breast cancer. Although mutations in individual genes occur relatively rarely, combined activating mutations in PIK3CA and AKT1, with inactivating mutations in PTEN, occur in approximately 25-30% of advanced TNBC. Recent randomised trials suggest improved progression-free survival (PFS) with AKT-inhibitors in combination with first-line chemotherapy for patients with TNBC and pathway genetic aberrations. We review the evidence for PI3 kinase pathway activation in TNBC, and clinical trial data for PI3 kinase, AKT and mTOR inhibitors in TNBC. We discuss uncertainty over defining which cancers have pathway activation and the future overlap between immunotherapy and pathway targeting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Liaw, D., Marsh, D. J., Li, J., Dahia, P. L. M., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacoke, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-64 · Cited by 2,091
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
Pereira, B., Chin, S.-F., Rueda, O. M., Vollan, H.-K. M., Provenzano, E., Bardwell, H. A., Pugh, M., Jones, L., Russell, R., Sammut, S.-J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11479 · Cited by 1,717
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,396
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
Essential role for nuclear PTEN in maintaining chromosomal integrity
Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., & Yin, Y. (2007) · Cell · doi:10.1016/j.cell.2006.11.042 · Cited by 979
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
The functions and regulation of the PTEN tumour suppressor: new modes and prospects
Lee, Y.-R., Chen, M., & Pandolfi, P. P. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0015-0 · Cited by 917
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 912
Li, D., & Sun, H. (1997) · PubMed · Cited by 866
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
Hollander, M. C., Blumenthal, G. M., & Dennis, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3037 · Cited by 794
Emens, L. A., Cruz, C., Eder, J. P., Braiteh, F., Chung, C., Tolaney, S. M., Kuter, I., Nanda, R., Cassier, P. A., Delord, J.-P., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4224 · Cited by 766
Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S. H., Zhang, J., Signoretti, S., Loda, M., Roberts, T. M., et al. (2008) · Nature · doi:10.1038/nature07091 · Cited by 688
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Zhang, Y., Kwok-Shing Ng, P., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., de Velasco, G., Jeong, K. J., Akbani, R., Hadjipanayis, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.013 · Cited by 626
Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., Anton, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 601
Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition
Irie, H. Y., Pearline, R. V., Grueneberg, D., Hsia, M., Ravichandran, P., Kothari, N., Natesan, S., & Brugge, J. S. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505087 · Cited by 589
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
PTEN-deficient cancers depend on PIK3CB
Wee, S., Wiederschain, D., Maira, S.-M., Loo, A., Miller, C., deBeaumont, R., Stegmeier, F., Yao, Y.-M., & Lengauer, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802655105 · Cited by 545
Baselga, J., Im, S.-A., Iwata, H., Cortés, J., De Laurentiis, M., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 533
Serra, V, Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodriguez, O., Guzman, M., Rodriguez, S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.626 · Cited by 528
The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2
Huang, J., Dibble, C. C., Matsuzaki, M., & Manning, B. D. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00289-08 · Cited by 511
George, S., Miao, D., Demetri, G. D., Adeegbe, D., Rodig, S. J., Shukla, S., Lipschitz, M., Amin-Mansour, A., Raut, C. P., Carter, S. L., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.001 · Cited by 483
Kim, S.-B., Dent, R., Im, S.-A., Espié, M., Blau, S., Tan, A. R., Isakoff, S. J., Oliveira, M., Saura, C., Wongchenko, M. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30450-3 · Cited by 478
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
LoRusso, P. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0018 · Cited by 470
Poggio, F., Bruzzone, M., Ceppi, M., Pondé, N. F., La Valle, G., Del Mastro, L., de Azambuja, E., & Lambertini, M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy127 · Cited by 468
Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0336 · Cited by 465
Gewinner, C., Wang, Z. C., Richardson, A., Teruya-Feldstein, J., Etemadmoghadam, D., Bowtell, D., Barretina, J., Lin, W. M., Rameh, L., Salmena, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.006 · Cited by 461
Accelerating Discovery of Functional Mutant Alleles in Cancer
Chang, M. T., Bhattarai, T. S., Schram, A. M., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., Chakravarty, D., Phillips, S., Kandoth, C., Penson, A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0321 · Cited by 409
Bareche, Y., Venet, D., Ignatiadis, M., Aftimos, P., Piccart, M., Rothe, F., & Sotiriou, C. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy024 · Cited by 382
Di Leo, A., Johnston, S., Lee, K. S., Ciruelos, E., Lønning, P. E., Janni, W., O'Regan, R., Mouret-Reynier, M.-A., Kalev, D., Egle, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30688-5 · Cited by 381
Lehmann, B. D., Bauer, J. A., Schafer, J. M., Pendleton, C. S., Tang, L., Johnson, K. C., Chen, X., Balko, J. M., Gómez, H., Arteaga, C. L., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0406-x · Cited by 342
André, F., & Zielinski, C. C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds195 · Cited by 329
de Bono, J. S., De Giorgi, U., Rodrigues, D. N., Massard, C., Bracarda, S., Font, A., Arranz Arija, J. A., Shih, K. C., Radavoi, G. D., Xu, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0981 · Cited by 311
(2000) · PubMed · Cited by 310
Hurvitz, S. A., Andre, F., Jiang, Z., Shao, Z., Mano, M. S., Neciosup, S. P., Tseng, L.-M., Zhang, Q., Shen, K., Liu, D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00051-0 · Cited by 306
Lin, J., Sampath, D., Nannini, M. A., Lee, B. B., Degtyarev, M., Oeh, J., Savage, H., Guan, Z., Hong, R., Kassees, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3072 · Cited by 294
Fedele, C. G., Ooms, L. M., Ho, M., Vieusseux, J., O'Toole, S. A., Millar, E. K., Lopez-Knowles, E., Sriratana, A., Gurung, R., Baglietto, L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015245107 · Cited by 283
Cancer-Associated PTEN Mutants Act in a Dominant-Negative Manner to Suppress PTEN Protein Function
Papa, A., Wan, L., Bonora, M., Salmena, L., Song, M. S., Hobbs, R. M., Lunardi, A., Webster, K., Ng, C., Newton, R. H., et al. (2014) · Cell · doi:10.1016/j.cell.2014.03.027 · Cited by 276
A novel AKT3 mutation in melanoma tumours and cell lines
Davies, M. A., Stemke-Hale, K., Tellez, C., Calderone, T. L., Deng, W., Prieto, V. G., Lazar, A. J. F., Gershenwald, J. E., & Mills, G. B. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604637 · Cited by 272
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
Asghar, U. S., Barr, A. R., Cutts, R., Beaney, M., Babina, I., Sampath, D., Giltnane, J., Lacap, J. A., Crocker, L., Young, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0369 · Cited by 268
Self-citationTargeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer
Baselga, J. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-12 · Cited by 261
Matulonis, U. A., Wulf, G. M., Barry, W. T., Birrer, M., Westin, S. N., Farooq, S., Bell-McGuinn, K. M., Obermayer, E., Whalen, C., Spagnoletti, T., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw672 · Cited by 219
Marty, B., Maire, V., Gravier, E., Rigaill, G., Vincent-Salomon, A., Kappler, M., Lebigot, I., Djelti, F., Tourdès, A., Gestraud, P., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2204 · Cited by 216
Byrski, T., Dent, R., Blecharz, P., Foszczynska-Kloda, M., Gronwald, J., Huzarski, T., Cybulski, C., Marczyk, E., Chrzan, R., Eisen, A., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3231 · Cited by 210
Basho, R. K., Gilcrease, M., Murthy, R. K., Helgason, T., Karp, D. D., Meric-Bernstam, F., Hess, K. R., Herbrich, S. M., Valero, V., Albarracin, C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5281 · Cited by 188
Martín, M., Chan, A., Dirix, L., O’Shaughnessy, J., Hegg, R., Manikhas, A., Shtivelband, M., Krivorotko, P., Batista López, N., Campone, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw562 · Cited by 180
An Activating Mutation of AKT2 and Human Hypoglycemia
Hussain, K., Challis, B., Rocha, N., Payne, F., Minic, M., Thompson, A., Daly, A., Scott, C., Harris, J., Smillie, B. J. L., et al. (2011) · Science · doi:10.1126/science.1210878 · Cited by 178
Saura, C., Roda, D., Roselló, S., Oliveira, M., Macarulla, T., Pérez-Fidalgo, J. A., Morales-Barrera, R., Sanchis-García, J. M., Musib, L., Budha, N., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0512 · Cited by 172
André, F., Hurvitz, S., Fasolo, A., Tseng, L.-M., Jerusalem, G., Wilks, S., O’Regan, R., Isaacs, C., Toi, M., Burris, H. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9161 · Cited by 166
Targeting Akt3 Signaling in Triple-Negative Breast Cancer
Chin, Y. R., Yoshida, T., Marusyk, A., Beck, A. H., Polyák, K., & Toker, A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2175 · Cited by 157
Banerji, U., Dean, E. J., Fidalgo, J. A. P., Batist, G., Bedard, P. L., You, B., Westin, S. N., Kabos, P., Garrett, M. D., Tall, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2260 · Cited by 154
Li, S., Shen, Y., Wang, M., Yang, J., Lv, M., Li, P., Chen, Z., & Jin, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.16761 · Cited by 150
Riggio, M., Perrone, M. C., Polo, M. L., Rodriguez, M. J., May, M., Abba, M. C., Lanari, C., & Novaro, V. (2017) · Scientific Reports · doi:10.1038/srep44244 · Cited by 149
Dolly, S. O., Wagner, A. J., Bendell, J. C., Kindler, H. L., Krug, L. M., Seiwert, T. Y., Zauderer, M. G., Lolkema, M. P., Apt, D., Yeh, R.-F., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2225 · Cited by 143
Baselga, J. M., Dent, S. F., Cortés, J., Im, Y., Dieras, V. C., Harbeck, N., Krop, I. E., Verma, S., Wilson, T. R., Jin, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.18_suppl.lba1006 · Cited by 138
Shapiro, G. I., Bell‐McGuinn, K. M., Molina, J. R., Bendell, J. C., Spicer, J. F., Kwak, E. L., Pandya, S. S., Millham, R., Borzillo, G. V., Pierce, K. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1306 · Cited by 137
Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype
Garcia, J. M., Silva, J. M., Domínguez, G., Gonzalez, R. M., Navarro, A., Carretero, L., Provencio, M., España, P., & Bonilla, F. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006273516976 · Cited by 133
Differential Expression of PTEN-Targeting MicroRNAs miR-19a and miR-21 in Cowden Syndrome
Pezzolesi, M. G., Platzer, P., Waite, K. A., & Eng, C. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.04.005 · Cited by 106
A Phase 2 study of perifosine in advanced or metastatic breast cancer
Leighl, N. B., Dent, S. F., Clemons, M. J., Vandenberg, T. A., Tozer, R. G., Warr, D. G., Crump, R. M., Hedley, D. W., Pond, G. R., Dancey, J. E., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9584-x · Cited by 91
Turner, N. C., Alarcon-Rozas, A. E., Armstrong, A. C., Philco, M., Chuken, Y. A. L., Sablin, M., Tamura, K., Villanueva, A. G., Fidalgo, J. A. P., Cheung, S. Y. A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz086 · Cited by 89
Self-citationINPP4B Is a PtdIns(3,4,5)P3 Phosphatase That Can Act as a Tumor Suppressor
Kofuji, S., Kimura, H., Nakanishi, H., Nanjo, H., Takasuga, S., Liu, H., Eguchi, S., Nakamura, R., Itoh, R., Ueno, N., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1329 · Cited by 88
Won, J., Gao, D., Chow, C., Cheng, J., Lau, S., Ellis, M. J., Perou, C. M., Bernard, P. S., & Nielsen, T. O. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.97 · Cited by 78
Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity
Yi, K. H., & Lauring, J. D. (2015) · Oncotarget · doi:10.18632/oncotarget.6648 · Cited by 77
Burnett, J., Körkaya, H., Ouzounova, M., Jiang, H., Conley, S. J., Newman, B. W., Sun, L., Connarn, J. N., Chen, C., Zhang, N., et al. (2015) · Scientific Reports · doi:10.1038/srep15821 · Cited by 70
WICKI, A. N., Brown, N. F., Xyrafas, A., Bize, V., Hawle, H., Berardi, S., Cmiljanović, N., Cmiljanović, V., Stumm, M., Dimitrijević, S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.03.012 · Cited by 68
Schmid, P., Abraham, J., Chan, S. Y. T., Wheatley, D. A., Brunt, M., Nemsadze, G., Baird, R. D., Park, Y. H., Hall, P. S., Perren, T. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1007 · Cited by 61
Self-citationBeg, S., Siraj, A. K., Prabhakaran, S., Jehan, Z., Ajarim, D. S., Al‐Dayel, F., Tulbah, A. M., & Al-Kuraya, K. S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3430-3 · Cited by 59
Wu, Y., Sarkissyan, M., Elshimali, Y., & Vadgama, J. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078259 · Cited by 59
Turner, N. C., Telli, M. L., Rugo, H. S., Mailliez, A., Ettl, J., Grischke, E., Mina, L. A., Balmañà, J., Fasching, P. A., Hurvitz, S. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1007 · Cited by 54
Self-citationXu, S., Li, S., Guo, Z., Luo, J. R., Ellis, M. J., & Ma, C. X. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0159 · Cited by 47
André, F., Campone, M., Ciruelos, E. M., Iwata, H., Loibl, S., Rugo, H. S., Wilke, C., Mills, D., Chol, M., Longin, A.-S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.tps618 · Cited by 15
Cited by
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Bianchini, G., De Angelis, C., Licata, L., & Gianni, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00565-2 · Cited by 1,382
PI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 476
Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Recent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 331
Triple negative breast cancer: A thorough review of biomarkers
da Silva, J. L., Cardoso Nunes, N. C., Izetti, P., de Mesquita, G. G., & de Melo, A. C. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102855 · Cited by 270
Metadata
- Authors
- Pascual, J., & Turner, N. C.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 30
- Issue
- 7
- Pages
- 1051-1060
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2943363006
- Cited by
- 333
- References
- 88
- FWCI
- 9.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.